

Chao Han

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11913088/publications.pdf>

Version: 2024-02-01

16
papers

395
citations

1040056

9
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

638
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 358-362.	2.8	186
2	Interaction of Macrolide Antibiotics with Intestinally Expressed Human and Rat Organic Anion-Transporting Polypeptides. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2375-2382.	3.3	44
3	Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation-Positive Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 955-961.	2.0	35
4	Involvement of Intestinal Uptake Transporters in the Absorption of Azithromycin and Clarithromycin in the Rat. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2492-2498.	3.3	34
5	Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 4436-4440.	2.2	24
6	Pharmacokinetics and Immunogenicity Investigation of a Human Anti-Interleukin-17 Monoclonal Antibody in Non-Naïve Cynomolgus Monkeys. <i>Drug Metabolism and Disposition</i> , 2015, 43, 762-770.	3.3	13
7	Improved gas chromatographic assay for the simultaneous determination of nitroglycerin and its mono- and dinitrate metabolites. <i>Biomedical Applications</i> , 1992, 579, 237-245.	1.7	12
8	Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 13-21.	2.5	12
9	Monoclonal antibodies: interspecies scaling with minimal preclinical information. <i>Therapeutic Delivery</i> , 2011, 2, 359-368.	2.2	10
10	Pharmacokinetics of nitroglycerin and its four metabolites during nitroglycerin transdermal administration. <i>Biopharmaceutics and Drug Disposition</i> , 1994, 15, 179-183.	1.9	6
11	A novel approach for the simultaneous quantification of a therapeutic monoclonal antibody in serum produced from two distinct host cell lines. <i>MAbs</i> , 2013, 5, 150-161.	5.2	4
12	Endogenous inotropic factor-induced endothelium-dependent relaxation of vascular smooth muscle. <i>British Journal of Pharmacology</i> , 1996, 118, 228-232.	5.4	3
13	A phase 1, randomized study to assess the pharmacokinetic comparability of siltuximab derived from two different cell lines in healthy subjects. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 328-334.	1.6	3
14	A Novel Approach to Evaluate the Pharmacokinetic Biocomparability of a Monoclonal Antibody Derived from Two Different Cell Lines Using Simultaneous Crossover Design. <i>AAPS Journal</i> , 2014, 16, 125-128.	4.4	3
15	Blockade of Nitric Oxide Synthase Potentiates the Suppression of Vasodilators by Norepinephrine in the Hepatic Artery. <i>Nitric Oxide - Biology and Chemistry</i> , 1999, 3, 172-179.	2.7	2
16	Nitric oxide inhibits norepinephrine-induced hepatic vascular responses but potentiates hepatic glucose output. <i>Canadian Journal of Physiology and Pharmacology</i> , 1999, 78, 36-44.	1.4	1